Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".
Andreas Reif, A. Elif Anıl Yağcıoğlu, Istvan Bitter, Jozefien Buyze, Richard Frey, Dong-Jing Fu, Yordan Godinov, Lars Haggström, Yerkebulan Kambarov, René E Nielsen, Albino J Oliveira-Maia, Christian von Holt, Allan H. Young, Wiesław Jerzy Cubała
Eur Neuropsychopharmacol June 5, 2026 DOI: 10.1016/j.euroneuro.2026.112885 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Correspondence or reply Peer reviewed |
|---|---|
| Topics | Depression Esketamine |
| Key points | The authors argue that the ESCAPE-LTE study provides evidence for the long-term efficacy and safety of esketamine nasal spray in treatment-resistant depression, countering the commentary's criticisms. They contend that the study's design and results support its conclusions. |
Abstract
Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".